Welcome
Support Centre
18 April 2014 
ISRCTN Register - International Standard Randomized Controlled Trial Number
Trial registration
Unique identification scheme
International databases
home  |   my details  |   ISRCTN Register  |   mRCT  |   links  |   information  |   news
Find trials
ISRCTN Register
tips on searching

Registration
New application
Updating record

Information
introduction
governing board
ISRCTN FAQs
data set
letter of agreement
request information
guidance notes
statistics

[ Print-friendly version ]
MRC Adjuvant Gastric Infusional Chemotherapy Trial
ISRCTN ISRCTN93793971
DOI 10.1186/ISRCTN93793971
ClinicalTrials.gov identifier
EudraCT number
Public title MRC Adjuvant Gastric Infusional Chemotherapy Trial
Scientific title
Acronym MAGIC
Serial number at source ST02
Study hypothesis To investigate whether peri-operative chemotherapy prolongs survival
Lay summary
Ethics approval Not provided at time of registration
Study design Two armed, randomised controlled trial
Countries of recruitment United Kingdom
Disease/condition/study domain Gastrointestinal cancer
Participants - inclusion criteria 1. Histologically proven adenocarcinoma (Stage II or greater) of the lower third oesophagus or stomach, that is considered to be non-urgently resectable with no evidence of distant metastasis
2. Suitable and fit for cytotoxic chemotherapy
3. WHO performance status of 0 or 1
Participants - exclusion criteria 1. Other malignant disease other than non-melanomatous skin cancer or in situ carcinoma of the cervix;
2. previous cytotoxic chemotherapy or radiotherapy
Anticipated start date 20/06/1994
Anticipated end date 31/12/2001
Status of trial Completed
Patient information material
Target number of participants 500
Interventions Three cycles of pre- and post-operative ECF (Epirubicin, Cisplatin and 5-Fluorouracil) chemotherapy versus surgery alone.
Follow-up: all patients will be followed 6 monthly to 2 years then annually until death.
Primary outcome measure(s) 1. Survival time
2. Disease-free survival
3. Quality of life
4. Tumour response
Secondary outcome measure(s) Not provided at time of registration
Sources of funding Medical Research Council (UK)
Trial website
Publications Results on http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&dopt=Abstract&list_uids=16822992
Contact name Ms  Monica  Verma
  Address MRC Clinical Trials Unit
222 Euston Road
  City/town London
  Zip/Postcode NW1 2DA
  Country United Kingdom
  Email
Sponsor Medical Research Council (MRC) (UK)
  Address 20 Park Crescent
  City/town London
  Zip/Postcode W1B 1AL
  Country United Kingdom
  Tel +44 (0)20 7636 5422
  Fax +44 (0)20 7436 6179
  Email clinical.trial@headoffice.mrc.ac.uk
  Sponsor website: http://www.mrc.ac.uk
Date applied 06/04/2000
Last edited 14/09/2007
Date ISRCTN assigned 06/04/2000
Submit your trial protocol
Submit to Trials journal
Follow us on Twitter
© 2014 ISRCTN unless otherwise stated.